VEEV · Veeva Systems Inc

Veeva Systems (NYSE: VEEV) today announced the acquisition of Ostro, the leading brand engagement platform for life sciences that gives patients and doctors immediate, compliant answers through an easy-to-use AI-driven chat experience. Ostro-powered brand websites allow customers to easily ask questions and receive approved information, resources, and next steps in real-time. Leveraging this rich engagement data, Ostro also generates deep insights brands use to improve reach and engagement. Ostro utilizes a combination of conversational AI, semantic search, and industry-specific business rules and guardrails. Responses are 100% compliant and drawn from MLR-approved materials. Unlike other AI solutions, Ostro does not hallucinate or generate novel responses. "AI has changed how people get information. It's no longer about how much information you can put out there, it's about how easy it is for customers to get answers," said Veeva CEO Peter Gassner. "Ostro is leading the way in

Veeva Systems (NYSE: VEEV) today announced that AOP Health , an international leader in integrated therapies for rare diseases and critical care, is standardizing on applications across the Veeva Vault Platform to drive faster global growth. By connecting clinical research, development, quality, and commercialization on Veeva Development Cloud , Quality Cloud , Commercial Cloud , and Data Cloud , AOP Health can streamline operations, eliminate silos, and accelerate delivery of critical medicines to patients. "AOP Health's mission is to provide integrated therapy solutions that improve the lives of patients with rare and critical conditions. For almost 30 years, AOP Health has been dedicated to this purpose," said Bernard Seiser, vice president, Digital, Data, and IT at AOP Health. "By upgrading our technology foundation and connecting key teams from development to commercial, Veeva Industry Cloud for Life Sciences supports this longstanding work and empowers AOP Health to scale

Veeva Systems Inc. (NYSE: VEEV), a leading provider of industry cloud solutions for the global life sciences industry, today announced results for its fourth quarter and fiscal year ended January 31, 2026. "The agentic transformation underway represents a substantial opportunity for Veeva and life sciences," said CEO Peter Gassner. "With our core systems of record spanning the industry's most critical functions and unique datasets, we can deliver industry-specific AI deeply integrated into our applications. Our progress with Veeva AI and continued strong execution in Commercial Cloud, Development Cloud, and Quality Cloud will create significant value for the industry." Fiscal 2026 Fourth Quarter Results: Revenues : Total revenues for the fourth quarter were $836.0 million, up from $720.9 million one year ago, an increase of 16% year over year. Subscription revenues for the fourth quarter were $707.7 million, up from $608.6 million one year ago, an increase of 16% year over year. <br

Veeva Systems (NYSE: VEEV) today announced that more than 125 customers — from multiple top 20 biopharmas to companies across all major regions including the U.S., Europe and Japan — are now live on Veeva Vault CRM , the next generation of CRM for life sciences. With the success of Vault CRM and the availability of Veeva AI , Veeva is accelerating the industry's move to agentic CRM. The strong momentum behind Vault CRM reflects the clear business value of its deep industry and regional functionality, compliance, workflows, and agents. Vault CRM provides the foundation commercial and medical teams require to support the full product lifecycle and complex customer engagements, from initial market preparation and launches to optimizing the performance of mature brands. "More than 125 customers are already live with Vault CRM and on the fast path to agentic customer engagement," said Arno Sosna, president, CRM Suite, Veeva. "We're expanding that impact across the industry as we lead with

Veeva Systems (NYSE: VEEV) will announce financial results for its fourth quarter and full fiscal year, which ended January 31, 2026, after market close on March 4, 2026. Veeva will host a conference call and webcast that day at 2:00 p.m. PT (5:00 p.m. ET) to discuss its financial results. Veeva will post prepared remarks to its investor relations website at ir.veeva.com at approximately 1:05 p.m. PT (4:05 p.m. ET). A webcast replay will be available on the website following the live event. Event: Veeva Systems' Fiscal 2026 Fourth Quarter and Full Year Results Conference Call Date: Wednesday, March 4, 2026 Time: 2:00 p.m. PT (5:00 p.m. ET) Conference Call Registration: https://events.q4inc.com/analyst/403345563?pwd=06lfBYfp Webcast: ir.veeva.com About Veeva Systems Veeva delivers the industry cloud for life sciences with software, data, and business consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the

Veeva Systems (NYSE: VEEV) today announced that 13 of the top 20 biopharmas have standardized on Veeva Link Key People to enhance customer engagement and provide data for AI globally. Biopharmas of all sizes use Link Key People, with 38 new customers added and three of the top 20 biopharmas making it their global standard within the last year. "Access to Veeva Link Key People further strengthens data-driven decision-making, enhances laser-sharp targeting, and fosters more engaging HCP interactions — altogether benefiting patient healthcare. As ingested, Link Key People data has become an organic part of Bayer's Data DNA, it enriches the outputs of our agentic, AI-driven platforms, delivering more relevant and actionable business insights for the long-term benefit of patients," said Dr. Daniel Jardanhazi-Kurutz, deputy director for customer engagement at Bayer AG. Link Key People delivers value to medical and commercial teams by providing trusted insights, while analytics teams can use

Veeva Systems (NYSE: VEEV) today announced Veeva eSource , a new Veeva SiteVault application designed to significantly reduce manual clinical trial processes and increase data quality. Veeva eSource will eliminate paper at the site through a direct data capture application and streamline data through EDC integration, and EHR to EDC transfer. "I'm excited to see Veeva eSource in action; although there are other options in use by sites, traditional eSource is still incredibly time-consuming to program, complete, and transfer data from eSource to EDC," said Alisha Garibaldi, CEO, Skylight Health Research. "A seamless flow of data from Veeva eSource to EDC will reduce errors, minimize QC processing, and allow us to spend more time where it matters – with our patients." With Veeva eSource, clinical trial data flows from site to sponsor with less effort through: Electronic Health Record (EHR) Integration: Transfers relevant patient data into eSource, then on to EDC. Eliminating the

A new industry report shows that building an AI-ready infrastructure is a top priority for consumer product goods (CPG) companies. The State of AI in Consumer Goods Report found most (82%) respondents are actively consolidating legacy systems or transitioning from best-of-breed solutions into unified platforms. Moving to a platform can provide connectivity across systems for standardized data and processes, a critical requirement for applying AI use cases. A majority (72%) of CPG companies are using, preparing, or planning to adopt agentic AI to advance manufacturing operations, signaling a need for advanced systems and processes that can provide clean, standard data. Key insights from the research on the CPG industry technology landscape include: Barriers to AI remain : Current technology infrastructures are deterring organizations from deploying AI and machine learning. The top three challenges include compliance and security (60%), high costs and resources constraints (60%), and

Veeva Systems (NYSE: VEEV) today announced participation in the following investor conference: J.P. Morgan 2026 Healthcare Conference, San Francisco, CA. Brian Van Wagener, CFO, will present on Tuesday, January 13, 2026, at 1:30 p.m. Pacific Time. The above presentation will be webcast. Links to the live and archived webcast will be available on Veeva's investor relations website at https://ir.veeva.com . About Veeva Systems Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com . Veeva uses its ir.veeva.com website as a means of disclosing material non-public

Veeva Systems (NYSE: VEEV) and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced a long-term enterprise agreement that builds upon their long-standing relationship. The expanded partnership will help BioMarin increase speed, agility, operational efficiency, and optimize the healthcare professional and patient experience by further leveraging and providing strategic input into Veeva's software, data, services, and consulting products. "This strategic partnership marks an important next step in our digital evolution," said Alexander Hardy, President and Chief Executive Officer of BioMarin. "We are excited by the opportunity to combine our scientific capabilities with Veeva's technological leadership that we believe will enable us to bring our transformative medicines more quickly to patients around the world." "Our partnership with BioMarin has always been guided by a shared set of values, including product excellence, value realization, and customer success," said Veeva CEO Peter